FOR US HEALTHCARE PROFESSIONALS ONLY
The efficacy of INVEGA TRINZA® has been extensively evaluated1-4
Studied vs placebo for relapse prevention in a randomized clinical trial
Evaluated vs INVEGA SUSTENNA® in a randomized, double-blind study
Evaluated in an open-label study after 52 weeks of treatment with INVEGA TRINZA®
References: 1. INVEGA TRINZA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830-839. 3. Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharm. 2016;19(7):1-14. 4. Garcia-Portilla MP, Llorca PM, Maina G, et al. Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia. Ther Adv. Psychopharmacol. 2020;10:2045125320926347.